Clinical trial · Interventional
High Dose Chemo With Autologous BMT for Treatment of Metastatic Breast Cancer
High Dose Chemotherapy With Autologous Bone Marrow Transplantation in the Treatment of Metastatic Breast Cancer
NCT00584428CI-TRIAL-00041897completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the response rate and the response duration of high dose chemotherapy with autologous bone marrow transplantation as intensification following induction chemotherapy in metastatic breast cancer and to evaluate prospectively the subdivision of patients with metastatic breast cancer according to prognostic groups.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| High-Dose Chemo with Autologous BMT | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- interventionNames
- Procedure: High-Dose Chemo with Autologous BMT
Primary outcomes (1)
- measure
- Once 10 patients enrolled in the study ar followed for at least 6 months, a preliminary analysis of the data will occur.
- timeFrame
- Undetermined
Secondary outcomes (1)
- measure
- No secondary outcomes
- timeFrame
- Undetermined
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed diagnosis of breast cancer * Age 18-70 * Breast cancer at first clinical evidence of metastatic disease * Must have objectively measurable or evaluable disease or be in complete remission Exclusion Criteria: * Previous diagnosis of another invasive carcinaom within 10 years (except skin cancer) * CNS involvement
References
Publications (0)
Data not yet available
No reference posted for this study.